top of page

Xencor - Janssen CD28 Bispecific Antibody Collaboration

Sexton Riley LLP represented Janssen Biotech, Inc., a Johnson & Johnson company, in its December 2020 research collaboration agreement with Xencor, Inc. focused on the discovery of bispecific antibodies against CD28, an immune co-stimulatory receptor on T cells, and an undisclosed prostate tumor target.

bottom of page